Drug profile · INN
darunavir ethanolate
DARUNAVIR ETHANOLATE
darunavir ethanolate (DARUNAVIR ETHANOLATE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — darunavir ethanolate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
darunavir ethanolate (DARUNAVIR ETHANOLATE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is darunavir ethanolate?
darunavir ethanolate (DARUNAVIR ETHANOLATE) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for darunavir ethanolate?
DARUNAVIR ETHANOLATE is a marketed brand name for darunavir ethanolate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of darunavir ethanolate?
darunavir ethanolate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.